DYAI — DYADIC INTERNATIONAL INC

—
Nasdaq · Health Care · Biotechnology · CIK 1213809 ·
Last close
$0.32
Market Cap
$12.66M
52W High
$1.60
52W Low
$0.30
ADV30
91,454
Next earnings
2026-11-12
Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins. It has a research and development agreement with VTT Technical Research Centre of Finland, Ltd; license agreement with Rubic One Health to develop various livestock vaccines; sub-license agreement with Phibro Animal Health/Abic Biological Laboratories to develop vaccines and treatments for livestock diseases; and collaboration with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses. Dyadic International, Inc. was founded in 1979 and is headquartered in Jupiter, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 172,729 -202,386 -1,806,709 -1,357,041 7,933,674 3,926,803 10,511,370
Jun 2026 123,886 -860,279 -2,045,511 -2,123,884 6,536,531 1,425,364 8,923,775
Mar 2026 623,590 -168,250 -1,912,284 -1,954,683 7,809,573 4,247,269 8,217,305
Dec 2025 235,716 -148,892 -1,524,929 -1,567,263 9,945,725 4,622,331 8,713,315

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-7,403,841
Investing CF
$1,470,913
Financing CF
$4,940,695
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.23
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-97,529,675
Inventory
—
Receivables
$1,318,453
ST Investments
$1,688,355
EBIT TTM
$-7,174,774
Pretax Income TTM
$-7,621,842
Interest Exp TTM
$447,068
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,802,237
EBITDA
—
Free Cash Flow
$-4,809,161
Enterprise Value
$13,847,801
Total Cash
$3,113,719
Total Debt
$5,046,064
Shares Out
40,063,703
Trailing EPS
$-0.23
Book Value
$0.03
ROE
-2826.9%
ROA
-63.0%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,232,311 -7,145,916 -7,364,628 9,945,725 8,713,315 1,232,410 -5,702,221
Dec 2024 3,495,389 -5,878,261 -5,809,159 9,930,275 7,459,985 2,470,290 -3,974,806
Dec 2023 2,898,806 -8,191,322 -6,795,461 8,219,236 2,340,651 5,878,585 -6,726,755
Dec 2022 2,930,303 -10,115,760 -9,735,258 13,712,818 2,625,079 11,087,739 -8,083,775

TTM Snapshot

Revenues TTM
$3,802,237
NetIncome TTM
$-7,621,842
OpCashFlow TTM
—
Assets (Latest)
$6,536,531
Forward EPS
$-0.32

Peers — same industry

TickerNameMarket CapLastDaily %
ATYR aTYR PHARMA INC $12.47M $4.99 —
BCDA BioCardia, Inc. $11.93M $0.79 —
PASG Passage BIO, Inc. $13.58M $4.22 —
PLUR Pluri Inc. $14.09M $0.98 —
ESLA Estrella Immunopharma, Inc. $14.42M $0.33 —

News headlines (Yahoo Finance, 1h cache)

DYAI: First Product Sales Are Modest
2026-11-16 17:02 · Yahoo
Dyadic: 3 Key Takeaways for Long-Term Investors
2026-11-13 16:42 · Yahoo
Dyadic (DYAI) Q3 2026 Earnings Call Transcript
2026-11-13 16:13 · Yahoo
Dyadic International, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
Dyadic International Inc (DYAI) (Q3 2026) Earnings Call Highlights: Transferrin Breakthrough, ...
2026-11-13 05:02 · Yahoo
Dyadic Announces Third Quarter 2026 Financial Results and Recent Developments
2026-11-12 21:05 · Yahoo
Dyadic’s C1-Produced RSV and Malaria Antibodies Advance into Animal Studies Following Positive Independent Evaluations
2026-11-12 12:30 · Yahoo
Dyadic Applied BioSolutions, BRIG BIO and Strive Nutrition Announce a Strategic Collaboration to Accelerate the Commercialization of Precision-Fermented Alpha-Lactalbumin for Premium Nutrition Markets
2026-11-10 12:30 · Yahoo
Dyadic to Report Q3 2026 Financial Results and Host Conference Call on Thursday November 12, 2026
2026-10-30 20:05 · Yahoo
DYAI: Second Quarter Results
2026-08-14 17:02 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.